|
1) Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006; 132: 584-93
|
|
|
|
2) Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000; 96: 2943-50
|
|
|
|
|
|
3) Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002; 99: 4525-30
|
|
|
|
|
|
4) Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001; 15: 1950-61
|
|
|
|
|
|
5) Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001; 98: 210-6
|
|
|
|
|
|
6) Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008; 22: 1925-32
|
|
|
|
|
|
7) Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004; 4: 314-22
|
|
|
|
|
|
8) Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100: 3063-7
|
|
|
|
|
|
9) Chen N, Lau H, Kong L, et al. Pharmakokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects in hemodialysis. J Clin Pharmacol. 2007; 47: 1466-75
|
|
|
|
|
|
10) Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006; 108: 3458-64
|
|
|
|
|
|
11) Richardson P, Jagannath S, Hussein S, et al. A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood. 2005; 106: abstr 1565, ASH Annual Meeting
|
|
|
|
|
|
12) Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357: 2123-32
|
|
|
|
|
|
13) Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357: 2133-42
|
|
|
|
|
|
14) Bahlis NJ, Song K, Trieu Y, et al. Lenalidomide overcomes poor prognosis conferred by del13q and t(4; 14) but not del17p13 in multiple myeloma: Results of the Canadian MM016 trial. Blood. 2007; 110: abstract 3597, ASH Annual Meeting
|
|
|
|
|
|
15) Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005; 106: 4050-3
|
|
|
|
|
|
16) Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2007; 110: abstr 74, ASH Annual Meeting
|
|
|
|
|
|
17) Rajkumar SV, Jacobus S, Callander N, et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome. J Clin Oncol. 2008; 26: abstr 8504, ASCO Annual Meeting
|
|
|
|
|
|
18) Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007; 21: 2035-42
|
|
|
|
|
|
19) Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): Results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. Blood. 2007; 110: abstr 77, ASH Annual Meeting
|
|
|
|
|
|
20) Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol. 2007; 25: 4459-65
|
|
|
|
|
|
21) Anderson KC, Jagannath S, Jakubowiak A, et al. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma(MM). J Clin Oncol. 2008; 26: abstr 8545, ASCO Annual Meeting
|
|
|
|
|
|
22) Richardson PG, Lonial S, Jakubowiak A, et al. Safety and efficacy of lenalidomide(Len), bortezomib(Bz), and dexamethasone(Dex) in patients with newly diagnosed multiple myeloma(MM): A phase I/II study. J Clin Oncol. 2008; 26: abstr 8520, ASCO Annual Meeting
|
|
|
|
|